FDA warns of ‘grave’ knock-on effects from Eagle decision

29-05-2020

Rory O'Neill

FDA warns of ‘grave’ knock-on effects from Eagle decision

JHVEPhoto / shutterstock.com

The US Food and Drug Administration (FDA) has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.


FDA, Eagle Pharmaceuticals, Bendeka, bendamustine, orphan drug, DC Circuit, appeal, blood cancer

LSIPR